http://www.atriummed.com/ Hudson, N.H., Date: April 10, 2006 /PR/Newswire/-- Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for a new bio-absorbable coated surgical mesh product called C-QUR™ Mesh. http://www.atriummed.com/News/anmviewer.asp?a=10&z=1 Atrium Medical Corporation announced today that it has received US FDA 510(k) marketing clearance for a new vascular product called FLIXENE. Indicated for vascular access and arterial vascular reconstruction, FLIXENE vascular grafts offer the discriminating surgeon an exciting new alternative to traditional 20 to 30 year old vascular graft technologies. http://www.atriummed.com/News/anmviewer.asp?a=12&z=1 Atrium Medical Corporation’s Clinical Update newsletter, edited by Patricia Carroll, RN,BC, CEN, RRT was awarded the Will Solimene Award for Excellence in Medical Communication from the New England Chapter of the American Medical Writers Association. http://www.atriummed.com/News/anmviewer.asp?a=13&z=1 Atrium Medical Corporation announced today that it has received U.S. FDA 510K marketing clearance for a new vascular implant device called the iVENA™ Vascular Patch. Indicated for use in the surgical repair and closure of the vascular system, Atrium’s latest implant technology is an extremely thin, reinforced biomaterial that suggests unsurpassed surgical installation convenience, reduced blood loss and handling efficiency. http://www.atriummed.com/News/anmviewer.asp?a=15&z=1 http://www.atriummed.com/News/anmviewer.asp?a=19&z=1 Hudson, N.H., April 9, 2007 — Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for a new Omega 3 surgical mesh product called C-QURLite™ Mesh. http://www.atriummed.com/News/anmviewer.asp?a=20&z=1 Atrium Medical Corporation is pleased to announce that our soft and firm PVC Catheters are DEHP-Free. http://www.atriummed.com/News/anmviewer.asp?a=21&z=1 Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for two new Omega 3 surgical mesh products; C-QUR Edge™ V-Patch and C-QUR Lite™ V-Patch. http://www.atriummed.com/News/anmviewer.asp?a=22&z=1 Atrium Medical announced today that it has begun enrollment of the first patients for their CONFIRM 1, First-in-Man (FIM) drug eluting coronary stent clinical trial. Atrium’s European FIM clinical trial study is evaluating Atrium's CINATRA™ voclosporin coated coronary stent system. http://www.atriummed.com/News/anmviewer.asp?a=24&z=1 Atrium Medical Corporation® is pleased to announce the formation of its newest med-tech specialty healthcare division, Atrium Biosurgery™ http://www.atriummed.com/News/anmviewer.asp?a=25&z=1 Atrium Medical Corporation today announced that it is a winner of the Supplier Performance Award, presented by Premier Purchasing Partners, LP, the group purchasing unit of the Premier healthcare alliance. http://www.atriummed.com/News/anmviewer.asp?a=26&z=1 Atrium Medical is pleased to announce today that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™. Cinatra™ is indicated for the treatment of coronary artery occlusive disease. http://www.atriummed.com/News/anmviewer.asp?a=27&z=1 Dr. Francesco Prati of San Giovanni Hospital and the European Imaging Laboratory in Rome, Italy presented the interim results of the COCTAIL Study at the recent C3 cardiology meeting in Baltimore, Maryland and at the EuroPCR 2009 cardiology meeting in Barcelona, Spain. http://www.atriummed.com/News/anmviewer.asp?a=28&z=1 Atrium was recently featured in the New Hampshire Business Review, the state’s leading source for business news, analysis and commentary. The article, published in Friday’s edition, reinforces Atrium’s commitment to meeting the needs of patients around the world. http://www.atriummed.com/News/anmviewer.asp?a=29&z=1 Atrium Medical Corporation is proud to announce the release of the final results of the “COCTAIL Study,” a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology. http://www.atriummed.com/News/anmviewer.asp?a=30&z=1 Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. http://www.atriummed.com/News/anmviewer.asp?a=31&z=1 Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). http://www.atriummed.com/News/anmviewer.asp?a=32&z=1 Atrium Medical Corporation announced that the 1st patient was enrolled in the INFUSE AMI trial. INFUSE AMI is a multi-center, multi-national, prospective, randomized, single blind trial examining how patients with heart attacks are treated. http://www.atriummed.com/News/anmviewer.asp?a=33&z=1 Atrium Medical Corporation today announced that it is a winner of the Supplier Performance Award, presented by the Premier healthcare alliance. http://www.atriummed.com/News/anmviewer.asp?a=34&z=1 Atrium Medical Corporation, pioneering advancements in biological, mechanical and therapeutic solutions for soft tissue reinforcement, is proud to announce that the company was awarded a three-year national contract from Premier Purchasing Partners L.P., the group purchasing organization of Premier, Inc. http://www.atriummed.com/News/anmviewer.asp?a=35&z=1 http://www.atriummed.com/News/anmviewer.asp?a=39&z=1